{"entity":{"id":"nct06385080","kind":"trial","name":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","aka":["OrigAMI-4"],"tldr":"A phase 1/2 trial of Amivantamab, Pembrolizumab and Carboplatin in head and neck squamous cell carcinoma, run by Janssen Research & Development, LLC, now recruiting.","summary":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer is a phase 1/2 interventional study registered as NCT06385080 by Janssen Research & Development, LLC, with 287 participants planned, started 2024-04-22 and due to reach its primary completion in 2032-12-27. Interventions recorded: Amivantamab, Pembrolizumab, Paclitaxel and Carboplatin.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06385080","url":"https://clinicaltrials.gov/study/NCT06385080"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["bispecific-antibody"],"targets":[],"drugs":["amivantamab","pembrolizumab","carboplatin"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06385080","phase":"1/2","setting":"A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants With Head and Neck Squamous Cell Carcinoma","sponsor":"Janssen Research & Development, LLC","participation":[{"nct":"NCT06385080","source":"https://clinicaltrials.gov/study/NCT06385080","fetchedAt":"2026-10-07T16:54:36.402Z","studySha256":"7dcdb51c13038f37ed65ff4a1245bba32841e01cd81d0023a2151541b8ba690d","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-25","leadSponsor":"Janssen Research & Development, LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":287,"enrolmentType":"ESTIMATED","siteCount":56,"recruitingSiteCount":51,"countries":["China","France","Germany","Japan","Malaysia","Poland","South Korea","Spain","Taiwan","United Kingdom","United States"]}],"started":"2024-04-22","startedType":"actual","enrolled":287,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06385080/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"}],"drug":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}